tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide has been researched along with naltrexone in 3 studies
| Studies (tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide) | Trials (tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide) | Recent Studies (post-2010) (tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide) | Studies (naltrexone) | Trials (naltrexone) | Recent Studies (post-2010) (naltrexone) |
|---|---|---|---|---|---|
| 18 | 0 | 0 | 8,745 | 1,228 | 2,642 |
| Protein | Taxonomy | tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide (IC50) | naltrexone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0051 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0063 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.006 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.006 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.0319 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0093 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0377 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0076 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Desprat, C; Zajac, JM | 1 |
| Coudoré-Civiale, MA; Courteix, C; Eschalier, A; Fialip, J; Privat, AM; Zajac, JM | 1 |
| Ballet, S; Bourgoin, S; Braz, J; Cesselin, F; Hamon, M; Mauborgne, A; Zajac, JM | 1 |
3 other study(ies) available for tyrosyl-leucyl-n-methylphenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and naltrexone
| Article | Year |
|---|---|
Differential modulation of mu- and delta-opioid antinociception by neuropeptide FF receptors in young mice.
Topics: Age Factors; Analgesics, Opioid; Animals; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Male; Mice; Mice, Inbred Strains; Morphine; Naltrexone; Narcotic Antagonists; Neuropeptides; Nociceptors; Oligopeptides; Receptors, Neuropeptide; Receptors, Opioid, delta; Receptors, Opioid, mu | 1997 |
Spinal effect of a neuropeptide FF analogue on hyperalgesia and morphine-induced analgesia in mononeuropathic and diabetic rats.
Topics: Analgesia; Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hyperalgesia; Injections, Spinal; Male; Morphine; Naltrexone; Narcotic Antagonists; Nervous System Diseases; Oligopeptides; Pain; Rats; Rats, Sprague-Dawley; Somatostatin; Time Factors; Vocalization, Animal | 1999 |
The neuropeptide FF analogue, 1DMe, reduces in vivo dynorphin release from the rat spinal cord.
Topics: Animals; Dose-Response Relationship, Drug; Dynorphins; Injections, Spinal; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Oligopeptides; Peptide Fragments; Perfusion; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Somatostatin; Spinal Cord | 2002 |